The global synthetic biology market size reached USD 16.35 billion in 2023 and is estimated to cross around USD 148.93 billion by 2033 with a CAGR of 25% from 2024 to 2033.
The synthetic biology market is expanding at a significant growth rate due to the wide applications of synthetic biology in medicine, manufacturing, and agriculture sectors. It involves the genetic alteration of organisms to give them new abilities to deal with some of the most pressing challenges, such as the production of valuable substances like medicines and fuels and the enhancement of environmental sensing.
Research in this field constructs DNA sequences in the presence of existing genes and novel ones, introducing genome editing techniques to make exact changes. Some examples that scientists produce using synthetic biology include microorganisms harnessed for bioremediation, rice modified to produce beta-carotene, and genetically modified yeast to make rose oil substitutes.
Get a Sample: https://www.precedenceresearch.com/sample/2862
Synthetic Biology Market Key Insights
- North America dominated the synthetic biology market with the highest market share of 39.8% in 2023.
- Asia Pacific is expected to grow at the fastest rate during the forecast period.
- By technology, the PCR technology segment has contributed more than 28% of market share in 2023.
- By technology, the genome editing technology segment is expected to grow at a significant rate during the forecast period.
- By product, the oligonucleotide/oligo pools and synthetic DNA segment has generated the biggest market share of 35.6% in 2023.
- By product, the enzymes segment is expected to witness significant growth during the forecast period.
- By application, the healthcare segment has contributed the highest market share of 57.7% in 2023.
- By end-use, the biotechnology and pharmaceutical companies segment has held a major market share of 52.1% in 2023.
Synthetic Biology Market by Regional Outlook
North America led the market with the largest market share of 39.8% in 2023.
Synthetic biology has revolutionized the biotechnology field in North America, specifically in the U.S, using advanced principles of engineering and biotechnological techniques. Backed by investments in DNA sequencing and genome editing technologies, this field captured the largest market share.
Integrating these advances with computational tools such as artificial intelligence accelerates design and testing cycles in predictions toward the efficient modification of organisms. The major application of synthetic biology is in drug development. Researchers and scientists in the region collaborate with academic institutions, government departments, and private investors to bring new inventions to the market.
The market in Asia Pacific is expected to grow at the fastest rate during the forecast period due to rising investments in the biotech industry. Many countries, including India, China, Japan, and Singapore, have promoted synthetic biology through supportive policies, research programs, funding, and government initiatives. Furthermore, the rapid expansion of the biotech industry and the rising advancements in genomics and biotechnology are expected to fuel the market in the region.
Synthetic Biology Market Segments Outlook
Technology Outlook
The PCR technology segment led the synthetic biology market in 2023 owing to the increasing adoption of this technology in genomic research. PCR is a simple, efficient, fast, and highly sensitive technique that yields millions to billions of copies of the product of interest for sequencing and cloning. Since its discovery, PCR has found applications in genotyping, cloning, mutation detection, sequencing, microarrays, forensic science, and paternity testing.
Global Synthetic Biology Market Revenue, By Technology, 2022-2032 (US$ Bn)
| Technology | 2022 | 2023 | 2027 | 2032 |
| PCR | 3.75 | 4.59 | 10.59 | 33.15 |
| NGS | 2.95 | 3.59 | 8.20 | 25.27 |
| Bioprocessing | 1.61 | 1.96 | 4.43 | 13.51 |
| Genome Editing | 2.41 | 2.96 | 6.91 | 21.95 |
| Others | 2.68 | 3.26 | 7.32 | 22.15 |
The genome editing technology segment is expected to grow significantly during the forecast period.
Genome editing technology improves the precision of cell genome alteration, including integrating and regulating large fragments of gene clusters. Genome editing is more effective and saves time than other genetic alteration methods. One of the most popular examples of this technology is CRISPR-Cas9, which targets several genes simultaneously.
Product Outlook
The oligonucleotide segment dominated the market in 2023 due to its wide range of applications in genetic research and testing. This versatile molecule is essential for antisense oligonucleotides, small interfering RNA, DNA sequencing primers, and more to perform exact genetic manipulation and analysis.
- In April 2024, Asahi Kasei Bioprocess collaborated with Axolabs Therapeutics to build a cutting-edge oligonucleotide cGMP manufacturing facility in Berlin, Germany.
Global Synthetic Biology Market Revenue, By Product, 2022-2032 (US$ Bn)
| Product | 2022 | 2023 | 2027 | 2032 |
| Enzymes | 3.35 | 4.09 | 9.41 | 29.30 |
| Oligonucleotide/Oligo Pools & Synthetic DNA | 4.76 | 5.83 | 13.57 | 42.87 |
| Xeno-Nucleic Acids | 1.61 | 1.95 | 4.38 | 13.24 |
| Cloning Technologies Kits | 2.68 | 3.27 | 7.45 | 22.98 |
| Chassis Organism | 1.01 | 1.21 | 2.64 | 7.65 |
The enzymes segment is expected to witness significant growth during the forecast period.
Synthetic biology tools are used to engineer microbial enzymes for industrial uses. Modifications in performance and suitability are used in the context of large-scale industrial applications, food, beverages, pharmaceuticals, and biofuels and enzymes such as laccases, xylanases, inulinase, lipases, and amylases.
- In June 2024, Basecamp Research entered into a partnership with the Ferruz Laboratory at the Institute of Molecular Biology of Barcelona to reveal ZymCTRL (“enzyme control”), allowing users to create new enzyme sequences by inputting an enzyme identification code, specifying the desired activity.
Global Synthetic Biology Market Revenue, By Application, 2022-2032 (US$ Bn)
| Application | 2022 | 2023 | 2027 | 2032 |
| Healthcare | 7.77 | 9.42 | 21.08 | 63.37 |
| Non-Healthcare | 5.63 | 6.92 | 16.38 | 52.67 |
Application Outlook
The healthcare segment dominated the market in 2023 owing to the increasing genomic research. Synthetic biology (SynBio) has several applications in synthesizing enzymes, generating sustainable biofuels, and producing bio-based specialty products. SynBio supports rational drug design, cancer immunotherapy, and sustainability in medical practice.
In blood cancer research, breakthroughs include the development of Car-T therapy against lymphoma, which works by applying techniques of SynBio in modifying a patient’s immune system to replace the traditional chemotherapy against illnesses like Acute Lymphoblastic Leukemia.
End Use Outlook
The biotechnology and pharmaceutical companies segment dominated the market in 2023.
Synthetic biology is one of the methods of integration of heterologous pathways in designer cells, paving the way for efficient medical agent production and the optimization of natural product yields. It has become very important in medical research to generate genetic circuits targeting tumors and develop controllable release systems for therapeutic agents. It also targets highly complex immune diseases, infectious diseases, and metabolic disorders challenging conventional treatment methodologies.
- In June 2024, Cyrus Biotechnology is launching a business that is projected to expand access to the software technology of the company, with the potential of supporting innovation in drug development, agriculture, synthetic biology and manufacturing.
Global Synthetic Biology Market Revenue, By End-Use, 2022-2032 (US$ Bn)
| End-Use | 2022 | 2023 | 2027 | 2032 |
| Academic & Research Institutes | 3.35 | 4.10 | 9.55 | 30.19 |
| Pharma & Biotech Companies | 6.97 | 8.52 | 19.67 | 61.56 |
| Others | 3.08 | 3.73 | 8.23 | 24.29 |
Market Dynamics
Driver
Lesser wildlife exploitation
Synthetic biology has many applications in modern life, and some of them are related to conservation. It can provide alternatives to conventional products derived from wildlife, thereby reducing the demand for wildlife goods.
A synthetic substitute for horseshoe crab blood, an important biomedical commodity, has been developed that could minimize or totally remove the need to harvest endangered crabs. This development addresses conservation concerns and spurs the growth of the synthetic biology market.
Read Also: DNA Sequencing Market Size to Reach USD 51.31 Billion by 2034
Restraint
Safety and security concerns
Synthetic biology poses a serious threat to national security if it is used for nefarious purposes, such as producing new biological or chemical weapons.
Furthermore, computational tools utilized for synthetic biology are vulnerable to a variety of cyber threats, including automation hacking, through which bad actors might modify or steal information and potentially create dangerous products like drugs or weapons.
Opportunity
Rising area of applications
Research in synthetic biology is underway with respect to its potential applications in medicine, particularly in vaccine development. Optimizing the design of key molecules in synthetic biology helps to create vaccines against all viruses and their variants.
Synthetic biology can be used to enhance the process of drug discovery and development by employing AI and machine learning to screen DNA sequences for drug candidates at faster rates.
Synthetic Biology Market Companies
- Codexis, Inc.
- Bota Biosciences Inc.
- Creative Enzymes.
- Creative Biogene.
- Illumina, Inc.
- Enbiotix, Inc.
- New England Biolabs
- Merck Kgaa (Sigma-Aldrich Co. Llc)
- Novozymes
- Euro fins Scientific
- Scarab Genomics, Llc
- Pareto Bio, Inc.
- Synthetic Genomics Inc.
- Synthego
- Thermo Fisher Scientific, Inc.
Recent Developments
- On 31st January 2022, Ribbon Biolabs, a DNA synthesis firm, raised a EUR 18 series A financing fund. With this fund, the company facilitated commercial-scale manufacturing facilities and the expansion of DNA synthesis technology in the United States.
- On 30th November 2021, GenScript increased its gene synthesis production capabilities in the United States with fully automated sequencing and oligo synthesis platforms.
- On 20th November 2022, a strategy for optimizing the production of monoclonal antibodies along with other valuable proteins was discovered by researchers. MIT researchers have developed a way of using CRISPR proteins to precisely control the quantity of a specific protein produced in mammalian cells. This process is fine-tuned by synthesizing beneficial proteins, such as monoclonal antibodies, used to treat cancer and other diseases or other cellular behavior. In their most recent study, published in Nature Communications, the researchers proved that this mechanism may operate in many mammalian cells with astonishingly consistent results.
Market Segmentation:
By Technology
- PCR Technology
- NGS Technology
- Bioprocessing Technology
- Genome Editing Technology
- Other Technologies
By Product
- Enzymes
- Oligonucleotide/Oligo Pools and Synthetic DNA
- Xeno-Nucleic Acids
- Cloning Technologies Kits
- Chassis Organism
By Application
- Healthcare
- Non-Clinical
- Clinical
- Non-healthcare
- Specialty Chemicals
- Biotech Crops
- Bio-fuels
- Others
By End-Use
- Academic and Government Research Institutes
- Biotechnology and Pharmaceutical Companies
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
